Records and reports
This section refers to the section 4.9 of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE ICH E6(R2), including Addenda items. It provides an overview of the requirements to the trial records management and maintenance, as well as storage, and audit trail.
4.9 Records and Reports
ADDENDUM
4.9.0 The investigator/institution should maintain adequate and accurate source documents and trial records that include all pertinent observations on each of the site’s trial subjects. Source data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (e.g., via an audit trail).
4.9.1 The investigator should ensure the accuracy, completeness, legibility, and timeliness of the data reported to the sponsor in the CRFs and in all required reports.
4.9.2 Data reported on the CRF, that are derived from source documents, should be consistent with the source documents or the discrepancies should be explained.
4.9.3 Any change or correction to a CRF should be dated, initialed, and explained (if necessary) and should not obscure the original entry (i.e., an audit trail should be maintained); this applies to both written and electronic changes or corrections (see 5.18.4 (n)). Sponsors should provide guidance to investigators and/or the investigators' designated representatives on making such corrections. Sponsors should have written procedures to assure that changes or corrections in CRFs made by sponsor's designated representatives are documented, are necessary, and are endorsed by the investigator. The investigator should retain records of the changes and corrections.
4.9.4 The investigator/institution should maintain the trial documents as specified in Essential Documents for the Conduct of a Clinical Trial (see 8.) and as required by the applicable regulatory requirement(s). The investigator/institution should take measures to prevent accidental or premature destruction of these documents.
4.9.5 Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2-years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to be retained (see 5.5.12).
4.9.6 The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator/institution.
4.9.7 Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the investigator/institution should make available for direct access all requested trial-related records.
Clinical Research News
Připravované klinické studie
-
Chengdu Zenitar Biomedical Technology Co., LtdZatím nenabírámeObesity With Cardiovascular Risk StudyAustrálie
-
Immuneering CorporationZatím nenabírámeMetastatický nemalobuněčný karcinom plic | Lokálně pokročilý nemalobuněčný karcinom plic | Rakovina plic (NSCLC) | NSCLC (pokročilý nemalobuněčný karcinom plic) | Non-skvamózní nemalobuněčný karcinom plicSpojené státy
-
Florida International UniversityNational Institute of Mental Health (NIMH); Oregon Health and Science UniversityZatím nenabírámeAutismusSpojené státy
-
Envisioning Justice Solutions, IncNáborAgrese | Úzkost | Problémy s hněvem | Depresivní úzkostná porucha | Trauma a poruchy související se stresemSpojené státy
-
Istituto Auxologico ItalianoNáborObezita a nadváha | Obesity / OverweightItálie
-
National Heart, Lung, and Blood Institute (NHLBI)Zatím nenabírámeWaldenstromova makroglobulinémieSpojené státy
-
National Cancer Institute (NCI)Zatím nenabírámeNemalobuněčný karcinom plic | NSCLC | Rakovina plic | Rakovina prostaty | mCRPC | Metastatický karcinom prostaty odolný vůči kastraci | Epiteliální nádory brzlíku | TETs | Thymic Carcinomas | ThymomasSpojené státy
-
National Institutes of Health Clinical Center (CC)Zatím nenabírámeDárci krve | AferézaSpojené státy
-
National Heart, Lung, and Blood Institute (NHLBI)NáborMastné kyseliny, Omega-3 | Rybí olejeSpojené státy
-
National Institute of Dental and Craniofacial Research...Zatím nenabírámeObezita | Obstrukční spánková apnoe (OSA) | Maxilární hypoplazie | Mandibulární hypoplazie | Pediatric Obstructive Sleep Apnea (OSA) | Adeno-Tonsillar Hypertrophy | Intraoral ApplianceSpojené státy
-
National Institute of Mental Health (NIMH)NáborZdravýSpojené státy
-
National Heart, Lung, and Blood Institute (NHLBI)Zatím nenabírámeHypertrofické kardiomyopatie | Left Ventricular Outflow Obstruction | Systolic Anterior MotionSpojené státy
Clinical Research Jobs
-
United Kingdom - London
-
United States - Richmond
-
Poland - Warsaw
-
Serbia - Belgrade
-
India - Karnataka - Bengaluru
-
United States - Wilmington
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China